News Channels

11 Mar 2020 FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
11 Mar 2020 ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist
11 Mar 2020 NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
11 Mar 2020 Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
11 Mar 2020 Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS
11 Mar 2020 Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities
11 Mar 2020 Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors
11 Mar 2020 Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
10 Mar 2020 Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
10 Mar 2020 Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
10 Mar 2020 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
10 Mar 2020 First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors
10 Mar 2020 Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
10 Mar 2020 Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline
10 Mar 2020 Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
10 Mar 2020 Mesoblast to evaluate anti-inflammatory cell therapy remestemcel-L for treatment of COVID-19 lung disease
09 Mar 2020 GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias
09 Mar 2020 ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
09 Mar 2020 CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection
09 Mar 2020 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up